


Patent Claims

1. Compounds of the formula I



in which

X denotes N or CR¹,

R¹ denotes H, F, Cl, CH₃, CH₂OH, CH₂Cl, CH₂Br, CF₃, CHF₂ or CH₂F,

R² denotes H or A,

Y denotes Ar¹, Het¹ or Cyc,

Ar¹ denotes phenyl or naphthyl, which is unsubstituted or mono-, di- or trisubstituted by Hal, A, [C(R²)₂]_pOR², [C(R²)₂]_pN(R²)₂, [C(R²)₂]_pHet², NO₂, CN, [C(R²)₂]_pCOOR², [C(R²)₂]_pCON(R²)₂, NR²COA, NR²SO₂A, [C(R²)₂]_pSO₂N(R²)₂, S(O)_nA, COHet³, O[C(R²)₂]_mN(R²)₂, O[C(R²)₂]_pAr², O[C(R²)₂]_pHet², NHCOOA, NHCON(R²)₂, CHO and/or COA,

Ar² denotes phenyl, which is unsubstituted or mono- or disubstituted by Hal, A, [C(R²)₂]_pOR², [C(R²)₂]_pN(R²)₂, [C(R²)₂]_pHet³, NO₂, CN, [C(R²)₂]_pCOOR, [C(R²)₂]_pN(R²)₂, N(R²)₂COA, NR²SO₂A, [C(R²)₂]_pSO₂N(R²)₂, S(O)_nA, COHet³, O[C(R²)₂]_mN(R²)₂, O[C(R²)₂]_pHet³, NHCOOA, NHCON(R²)₂, CHO and/or COA,

Het¹ denotes pyrrolidinyl, azetidiny, tetrahydroimidazolyl, tetrahydrofuranyl, tetrahydropyrazolyl, tetrahydropyranyl, piperidinyl, morpholinyl, hexahydropyridazinyl, hexahydro-pyrimidinyl, [1,3]dioxolanyl, piperazinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl,

5 triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, quinolyl, 1,3-benzodioxolyl, benzothiophenyl, benzofuranyl, imidazopyridyl or furo[3,2-b]pyridyl, each of which is unsubstituted or mono- or disubstituted by Hal, A, $[C(R^2)_2]_pOR^2$, $[C(R^2)_2]_pN(R^2)_2$, $[C(R^2)_2]_pHet^2$, $[C(R^2)_2]_pAr^2$, NO_2 , CN, $[C(R^2)_2]_pCOOR^2$, $[C(R^2)_2]_pCON(R^2)_2$, NR^2COA , NR^2SO_2A , $[C(R^2)_2]_pSO_2N(R^2)_2$, $S(O)_nA$, $COHet^3$, $O[C(R^2)_2]_mN(R^2)_2$, $O[C(R^2)_2]_pAr^2$, $O[C(R^2)_2]_pHet^2$, $NHCOOA$, $NHCON(R^2)_2$, CHO, COA, =S, =NR and/or =O,

Cyc denotes cyclic alkyl with 3, 4, 5, 6 or 7 C-atoms, which may be unsubstituted or monosubstituted by A, Hal, CN or Ar^2 or Het^2 ,

15 Het^2 denotes pyrrolidinyl, azetidiny, tetrahydroimidazolyl, tetrahydrofuranyl, tetrahydropyrazolyl, tetrahydropyranyl, piperidinyl, morpholinyl, hexahydropyridazinyl, hexahydropyrimidinyl, [1,3]dioxolanyl, piperazinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, quinolyl, 1,3-benzodioxolyl, benzothiophenyl, benzofuranyl, imidazopyridyl or furo[3,2-b]pyridyl, each of which is unsubstituted or mono- or disubstituted by Hal, A, $[C(R^2)_2]_pOR^2$, $[C(R^2)_2]_pN(R^2)_2$, $[C(R^2)_2]_pHet^3$, $[C(R^2)_2]_pOHet^3$, $[C(R^2)_2]_pAr^2$, NO_2 , CN, $[C(R^2)_2]_pCOOR^2$, $[C(R^2)_2]_pCON(R^2)_2$, NR^2COA , NR^2SO_2A , $[C(R^2)_2]_pSO_2N(R^2)_2$, $S(O)_nA$, $COHet^3$, $O[C(R^2)_2]_mN(R^2)_2$, $O[C(R^2)_2]_pAr^2$, $O[C(R^2)_2]_pHet^3$, $NHCOOA$, $NHCON(R^2)_2$, CHO, COA, =S, =NR and/or =O,

30 Het^3 denotes dihydropyrrolyl, pyrrolidinyl, azetidiny, oxetanyl, tetrahydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, tetrahydrofuranyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, morpholinyl, hexahydropyridazinyl, hexahydropyrimidinyl,

[1,3]dioxolanyl, tetrahydropyranyl or piperazinyl, each of which is unsubstituted or mono- or disubstituted by Hal, CN, OR², COOR², CON(R²)₂, S(O)_nA, S(O)_nAr, COA, A and/or =O,

5 A denotes unbranched or branched alkyl with 1-10 C-atoms, wherein one or two non-adjacent CH- and/or CH₂-groups may be replaced by N-, O- and/or S-atoms and wherein 1-7 H-atoms may be replaced by F or Cl,

10 Hal denotes F, Cl, Br or I,

 n denotes 0, 1 or 2,

 m denotes 1, 2 or 3,

15 p denotes 0, 1, 2, 3 or 4,

with the proviso that, if R¹ is absent, then Y is not 4-fluorophenyl, 3-bromophenyl or 5-chloro-2-fluorophenyl,

20 and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

2. Compounds according to Claim 1 in which

25 Ar¹ denotes phenyl, which is monosubstituted by Hal, A, [C(R²)₂]_pHet² or [C(R²)₂]_pCOOR²,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

30 3. Compounds according to Claim 1 or 2 in which

 Het¹ denotes pyrrolidinyl, piperidinyl or pyrazolyl, each of which is unsubstituted or monosubstituted by A,

35 and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

4. Compounds according to one or more of Claims 1-3 in which
Het² denotes pyrrolidinyl, piperidinyl or pyrazolyl, each of which is
monosubstituted by A,
and pharmaceutically acceptable solvates, salts, tautomers and
stereoisomers thereof, including mixtures thereof in all ratios.
- 5.
5. Compounds according to one or more of Claims 1-4 in which
X denotes N, CH, CCF₃ or CCH₃,
and pharmaceutically acceptable solvates, salts, tautomers and
stereoisomers thereof, including mixtures thereof in all ratios.
- 10
6. Compounds according to one or more of Claims 1-5 in which
in which
- 15
- X denotes N, CH, CCF₃ or CCH₃,
R¹ denotes H, F, Cl or CH₃,
R² denotes H,
Y denotes Ar¹, Het¹ or Cyc,
Ar¹ denotes phenyl, which is monosubstituted by Hal, A,
[C(R²)₂]_pHet² or [C(R²)₂]_pCOOR²,
Het¹ denotes pyrrolidinyl, piperidinyl or pyrazolyl, each of which is
unsubstituted or monosubstituted by A,
Cyc denotes cyclic alkyl with 3, 4, 5, 6 or 7 C-atoms, which may be
unsubstituted or monosubstituted by A, Hal, CN or Ar² or Het²,
Het² denotes pyrrolidinyl, piperidinyl or pyrazolyl, each of which is
monosubstituted by A,
A denotes unbranched or branched alkyl with 1-10 C-atoms,
wherein one or two non-adjacent CH- and/or CH₂-groups may be
replaced by O-atoms and wherein 1-7 H-atoms may be replaced
by F or Cl,
- 20
- 25
- 30
- 35

Hal denotes F, Cl, Br or I,

p denotes 0 or 1,

with the proviso that, if R¹ is absent, then Y is not 4-fluorophenyl, 3-bromophenyl or 5-chloro-2-fluorophenyl,

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

7. Compounds according to Claim 1, selected from the group

No.	Name
"A1"	2-p-tolyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A2"	4-(4-oxo-3,4-dihydro-pyrrolo[2,1-f][1,2,4]triazin-2-yl)-benzoic acid methyl ester
"A3"	2-(4-tert-butyl-phenyl)-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A4"	2-(1-acetyl-piperidin-4-yl)-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A5"	2-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-3H-pyrrolo-[2,1-f][1,2,4]triazin-4-one
"A6"	2-(4-bromo-phenyl)-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A7"	2-[4-(1-methyl-1H-pyrazol-4-yl)-phenyl]-3H-pyrrolo-[2,1-f][1,2,4]triazin-4-one
"A8"	2-(4-pyrrolidin-1-ylphenyl)-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A9"	2-cyclohexyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A10"	2-(1-tert-butylpyrazol-4-yl)-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A11"	2-[4-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one

5

10

15

20

25


30

35

"A12"	6-fluoro-2-[4-(1-hydroxy-1-methyl-ethyl)phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A13"	6-methyl-2-[4-(1-methylpyrazol-4-yl)phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A14"	2-[4-(1-ethyl-1-hydroxy-propyl)-phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A15"	2-[4-[1-(2-hydroxy-ethoxy)-1-methyl-ethyl]-phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A16"	2-[4-(1-amino-1-methyl-ethyl)-phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A17"	6-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-2-methyl-5H-1,5,7,7a-tetraaza-inden-4-one
"A18"	6-chloro-2-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A19"	2-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-7-methyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A20"	2-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-7-trifluoromethyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A21"	2-[4-(1-hydroxy-cyclopentyl)-phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one

and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

8. Process for the preparation of compounds of the formula I according to Claims 1-7 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, characterised in that
- a compound of the formula II



in which X, R¹ and Y have the meanings indicated in Claim 1,

is reacted with NH₃, an anorganic base or an alkali alcoholate,

or

- b) a radical Y is converted into another radical Y by
 - i) converting a halogen atom into an ester group,
 - ii) converting an ester group into an alcohol group,
 - iii) converting in a Suzuki coupling a halogenated phenyl ring into an arylated phenyl ring,

and/or

a base or acid of the formula I is converted into one of its salts.


9. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, and optionally an pharmaceutically acceptable carrier, excipient or vehicle.
10. Compounds of the formula I and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, including mixtures thereof in all ratios, for the use for the treatment and/or prevention of cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.

- 5 11. Compounds according to claim 10 for the use for the treatment and/or prevention of diseases selected from the group cancer of head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors and blood-borne tumors.
- 10 12. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one
- 15 further medicament active ingredient.
- 20 13. Set (kit) consisting of separate packs of
- (a) an effective amount of a compound of the formula I and/or pharmaceutically acceptable salts, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,
- and
- (b) an effective amount of a further medicament active ingredi-
- 25 ent.
- 30
- 35

Patent Claims

1. Compounds of the formula I

5



10

in which

X denotes N or CR¹,

R¹ denotes H, F, Cl, CH₃, CH₂OH, CH₂Cl, CH₂Br, CF₃, CHF₂ or CH₂F,

15

R² denotes H or A,

Y denotes Ar¹, Het¹ or Cyc,

Ar¹ denotes phenyl or naphthyl, which is unsubstituted or mono-, di- or trisubstituted by Hal, A, [C(R²)₂]_pOR², [C(R²)₂]_pN(R²)₂, [C(R²)₂]_pHet², NO₂, CN, [C(R²)₂]_pCOOR², [C(R²)₂]_pCON(R²)₂, NR²COA, NR²SO₂A, [C(R²)₂]_pSO₂N(R²)₂, S(O)_nA, COHet³, O[C(R²)₂]_mN(R²)₂, O[C(R²)₂]_pAr², O[C(R²)₂]_pHet², NHCOOA, NHCON(R²)₂, CHO and/or COA,

20

25

Ar² denotes phenyl, which is unsubstituted or mono- or disubstituted by Hal, A, [C(R²)₂]_pOR², [C(R²)₂]_pN(R²)₂, [C(R²)₂]_pHet³, NO₂, CN, [C(R²)₂]_pCOOR, [C(R²)₂]_pN(R²)₂, N(R²)₂COA, NR²SO₂A, [C(R²)₂]_pSO₂N(R²)₂, S(O)_nA, COHet³, O[C(R²)₂]_mN(R²)₂, O[C(R²)₂]_pHet³, NHCOOA, NHCON(R²)₂, CHO and/or COA,

30

Het¹ denotes pyrrolidinyl, azetidiny, tetrahydroimidazolyl, tetrahydrofuranyl, tetrahydropyrazolyl, tetrahydropyranlyl, piperidinyl, morpholinyl, hexahydropyridazinyl, hexahydro-pyrimidinyl, [1,3]dioxolanyl, piperazinyl, furyl, thienyl, pyrrolyl, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl,

35

- triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, quinolyl, 1,3-benzodioxolyl, benzothiophenyl, benzofuranyl, imidazopyridyl or furo[3,2-b]pyridyl, each of which is unsubstituted or mono- or
- 5 disubstituted by Hal, A, $[C(R^2)_2]_pOR^2$, $[C(R^2)_2]_pN(R^2)_2$, $[C(R^2)_2]_pHet^2$, $[C(R^2)_2]_pAr^2$, NO_2 , CN, $[C(R^2)_2]_pCOOR^2$, $[C(R^2)_2]_pCON(R^2)_2$, NR^2COA , NR^2SO_2A , $[C(R^2)_2]_pSO_2N(R^2)_2$, $S(O)_nA$, $COHet^3$, $O[C(R^2)_2]_mN(R^2)_2$, $O[C(R^2)_2]_pAr^2$,
- 10 $O[C(R^2)_2]_pHet^2$, $NHCOOA$, $NHCON(R^2)_2$, CHO, COA, =S, =NR and/or =O,
- Cyc denotes cyclic alkyl with 3, 4, 5, 6 or 7 C-atoms, which may be unsubstituted or monosubstituted by A, Hal, CN or Ar^2 or Het^2 ,
- 15 Het^2 denotes pyrrolidinyl, azetidiny, tetrahydroimidazolyl, tetrahydrofuranyl, tetrahydropyrazolyl, tetrahydropyranyl, piperidinyl, morpholinyl, hexahydropyridazinyl, hexahydro-pyrimidinyl, [1,3]dioxolanyl, piperazinyl, furyl, thienyl, pyrrolyl,
- 20 imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, triazolyl, tetrazolyl, pyridyl, pyrimidyl, pyridazinyl, indolyl, isoindolyl, benzimidazolyl, indazolyl, quinolyl, 1,3-benzodioxolyl, benzothiophenyl, benzofuranyl, imidazopyridyl or furo[3,2-b]pyridyl, each of which is unsubstituted or mono- or
- 25 disubstituted by Hal, A, $[C(R^2)_2]_pOR^2$, $[C(R^2)_2]_pN(R^2)_2$, $[C(R^2)_2]_pHet^3$, $[C(R^2)_2]_pOHet^3$, $[C(R^2)_2]_pAr^2$, NO_2 , CN, $[C(R^2)_2]_pCOOR^2$, $[C(R^2)_2]_pCON(R^2)_2$, NR^2COA , NR^2SO_2A , $[C(R^2)_2]_pSO_2N(R^2)_2$, $S(O)_nA$, $COHet^3$, $O[C(R^2)_2]_mN(R^2)_2$,
- 30 $O[C(R^2)_2]_pAr^2$, $O[C(R^2)_2]_pHet^3$, $NHCOOA$, $NHCON(R^2)_2$, CHO, COA, =S, =NR and/or =O,
- Het^3 denotes dihydropyrrolyl, pyrrolidinyl, azetidiny, oxetanyl, tetrahydroimidazolyl, dihydropyrazolyl, tetrahydropyrazolyl,
- 35 tetrahydrofuranyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, morpholinyl, hexahydropyridazinyl, hexahydropyrimidinyl,

- [1,3]dioxolanyl, tetrahydropyranyl or piperazinyl, each of which is unsubstituted or mono- or disubstituted by Hal, CN, OR², COOR², CON(R²)₂, S(O)_nA, S(O)_nAr, COA, A and/or =O,
- 5 A denotes unbranched or branched alkyl with 1-10 C-atoms, wherein one or two non-adjacent CH- and/or CH₂-groups may be replaced by N-, O- and/or S-atoms and wherein 1-7 H-atoms may be replaced by F or Cl,
- 10 Hal denotes F, Cl, Br or I,
 n denotes 0, 1 or 2,
 m denotes 1, 2 or 3,
 p denotes 0, 1, 2, 3 or 4,
- 15 with the proviso that, if R¹ is absent, then Y is not 4-fluorophenyl, 3-bromophenyl or 5-chloro-2-fluorophenyl, and excluding
- 20 tert-butyl 2-(4-oxo-3H-pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidine-1-carboxylate and benzyl 2-(4-oxo-3H-pyrrolo[2,1-f][1,2,4]triazin-2-yl)pyrrolidine-1-carboxylate,
- 25 and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
2. Compounds according to Claim 1 in which
- 30 Ar¹ denotes phenyl, which is monosubstituted by Hal, A, [C(R²)₂]_pHet² or [C(R²)₂]_pCOOR², and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.
- 35 3. Compounds according to Claim 1 or 2 in which

Het¹ denotes pyrrolidinyl, piperidinyl or pyrazolyl, each of which is unsubstituted or monosubstituted by A, and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

5

4. Compounds according to one or more of Claims 1-3 in which Het² denotes pyrrolidinyl, piperidinyl or pyrazolyl, each of which is monosubstituted by A, and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

10

15

5. Compounds according to one or more of Claims 1-4 in which X denotes N, CH, CCF₃ or CCH₃, and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

20

6. Compounds according to one or more of Claims 1-5 in which in which

X denotes N, CH, CCF₃ or CCH₃,

R¹ denotes H, F, Cl or CH₃,

25

R² denotes H,

Y denotes Ar¹, Het¹ or Cyc,

Ar¹ denotes phenyl, which is monosubstituted by Hal, A, [C(R²)₂]_pHet² or [C(R²)₂]_pCOOR²,

30

Het¹ denotes pyrrolidinyl, piperidinyl or pyrazolyl, each of which is unsubstituted or monosubstituted by A,

Cyc denotes cyclic alkyl with 3, 4, 5, 6 or 7 C-atoms, which may be unsubstituted or monosubstituted by A, Hal, CN or Ar² or Het²,

35

Het² denotes pyrrolidinyl, piperidinyl or pyrazolyl, each of which is monosubstituted by A,

A denotes unbranched or branched alkyl with 1-10 C-atoms,
wherein one or two non-adjacent CH- and/or CH₂-groups may be
replaced by O-atoms and wherein 1-7 H-atoms may be replaced
by F or Cl,

5

Hal denotes F, Cl, Br or I,

p denotes 0 or 1,

10

with the proviso that, if R¹ is absent, then Y is not 4-fluorophenyl, 3-
bromophenyl or 5-chloro-2-fluorophenyl,

and pharmaceutically acceptable solvates, salts, tautomers and
stereoisomers thereof, including mixtures thereof in all ratios.

15

7. Compounds according to Claim 1, selected from the group

20


No.	Name
"A1"	2-p-tolyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A2"	4-(4-oxo-3,4-dihydro-pyrrolo[2,1-f][1,2,4]triazin-2-yl)-benzoic acid methyl ester
"A3"	2-(4-tert-butyl-phenyl)-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
25 "A4"	2-(1-acetyl-piperidin-4-yl)-3H-pyrrolo[2,1-f][1,2,4]triazin-4- one
"A5"	2-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-3H-pyrrolo- [2,1-f][1,2,4]triazin-4-one
30 "A6"	2-(4-bromo-phenyl)-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
"A7"	2-[4-(1-methyl-1H-pyrazol-4-yl)-phenyl]-3H-pyrrolo- [2,1-f][1,2,4]triazin-4-one
"A8"	2-(4-pyrrolidin-1-ylphenyl)-3H-pyrrolo[2,1-f][1,2,4]triazin-4- one
35 "A9"	2-cyclohexyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one

	"A10"	2-(1-tert-butylpyrazol-4-yl)-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
5	"A11"	2-[4-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
	"A12"	6-fluoro-2-[4-(1-hydroxy-1-methyl-ethyl)phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
10	"A13"	6-methyl-2-[4-(1-methylpyrazol-4-yl)phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
	"A14"	2-[4-(1-ethyl-1-hydroxy-propyl)-phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
15	"A15"	2-[4-[1-(2-hydroxy-ethoxy)-1-methyl-ethyl]-phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
	"A16"	2-[4-(1-amino-1-methyl-ethyl)-phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
20	"A17"	6-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-2-methyl-5H-1,5,7,7a-tetraaza-inden-4-one
	"A18"	6-chloro-2-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
25	"A19"	2-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-7-methyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
	"A20"	2-[4-(1-hydroxy-1-methyl-ethyl)-phenyl]-7-trifluoromethyl-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one
	"A21"	2-[4-(1-hydroxy-cyclopentyl)-phenyl]-3H-pyrrolo[2,1-f][1,2,4]triazin-4-one

30 and pharmaceutically acceptable solvates, salts, tautomers and stereoisomers thereof, including mixtures thereof in all ratios.

8. Process for the preparation of compounds of the formula I according to Claims 1-7 and pharmaceutically acceptable salts, solvates, tautomers and stereoisomers thereof, characterised in that
- 35

a) a compound of the formula II



in which X, R¹ and Y have the meanings indicated in Claim 1,

10 is reacted with NH₃, an organic base or an alkali alcoholate,

or

15 b) a radical Y is converted into another radical Y by

i) converting a halogen atom into an ester group,

ii) converting an ester group into an alcohol group,

20 iii) converting in a Suzuki coupling a halogenated phenyl ring
into an arylated phenyl ring,

and/or

a base or acid of the formula I is converted into one of its salts.

25 9. Medicaments comprising at least one compound of the formula I
and/or pharmaceutically acceptable salts, solvates, tautomers and
stereoisomers thereof, including mixtures thereof in all ratios, and
optionally an pharmaceutically acceptable carrier, excipient or
30 vehicle.

10. Compounds of the formula I and pharmaceutically acceptable salts,
solvates, tautomers and stereoisomers thereof, including mixtures
35 thereof in all ratios, for the use for the treatment and/or prevention of

cancer, multiple sclerosis, cardiovascular diseases, central nervous system injury and different forms of inflammation.

- 5 11. Compounds according to claim 10 for the use for the treatment and/or prevention of diseases selected from the group cancer of head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, urinary bladder, uterine, cervix, breast, ovaries, testicles or other reproductive organs, skin, thyroid, blood, lymph nodes, kidney, liver, pancreas, brain, central nervous system, solid tumors and blood-borne tumors.
- 10
12. Medicaments comprising at least one compound of the formula I and/or pharmaceutically acceptable salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
- 15
- 20 13. Set (kit) consisting of separate packs of
 (a) an effective amount of a compound of the formula I and/or pharmaceutically acceptable salts, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios,
 and
 (b) an effective amount of a further medicament active ingredi-
 ent.
- 25
- 30
- 35